524 related articles for article (PubMed ID: 28239472)
21. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.
Zhao C; Tella SH; Del Rivero J; Kommalapati A; Ebenuwa I; Gulley J; Strauss J; Brownell I
J Clin Endocrinol Metab; 2018 Feb; 103(2):365-369. PubMed ID: 29220526
[TBL] [Abstract][Full Text] [Related]
22. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Dirix LY; Takacs I; Jerusalem G; Nikolinakos P; Arkenau HT; Forero-Torres A; Boccia R; Lippman ME; Somer R; Smakal M; Emens LA; Hrinczenko B; Edenfield W; Gurtler J; von Heydebreck A; Grote HJ; Chin K; Hamilton EP
Breast Cancer Res Treat; 2018 Feb; 167(3):671-686. PubMed ID: 29063313
[TBL] [Abstract][Full Text] [Related]
23. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
24. Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
Giles AJ; Hao S; Padget M; Song H; Zhang W; Lynes J; Sanchez V; Liu Y; Jung J; Cao X; Fujii R; Jensen R; Gillespie D; Schlom J; Gilbert MR; Nduom EK; Yang C; Lee JH; Soon-Shiong P; Hodge JW; Park DM
JCI Insight; 2019 Oct; 4(20):. PubMed ID: 31536478
[TBL] [Abstract][Full Text] [Related]
25. Product review: avelumab, an anti-PD-L1 antibody.
Collins JM; Gulley JL
Hum Vaccin Immunother; 2019; 15(4):891-908. PubMed ID: 30481100
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Hicks KC; Fantini M; Donahue RN; Schwab A; Knudson KM; Tritsch SR; Jochems C; Clavijo PE; Allen CT; Hodge JW; Tsang KY; Schlom J; Gameiro SR
Oncoimmunology; 2018; 7(11):e1466018. PubMed ID: 30377559
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
[TBL] [Abstract][Full Text] [Related]
28. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
Keilholz U; Mehnert JM; Bauer S; Bourgeois H; Patel MR; Gravenor D; Nemunaitis JJ; Taylor MH; Wyrwicz L; Lee KW; Kasturi V; Chin K; von Heydebreck A; Gulley JL
J Immunother Cancer; 2019 Jan; 7(1):12. PubMed ID: 30651126
[TBL] [Abstract][Full Text] [Related]
29. Avelumab for the treatment of urothelial cancer.
Rodriguez-Vida A; Bellmunt J
Expert Rev Anticancer Ther; 2018 May; 18(5):421-429. PubMed ID: 29540084
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
Stein A; Simnica D; Schultheiß C; Scholz R; Tintelnot J; Gökkurt E; von Wenserski L; Willscher E; Paschold L; Sauer M; Lorenzen S; Riera-Knorrenschild J; Depenbusch R; Ettrich TJ; Dörfel S; Al-Batran SE; Karthaus M; Pelzer U; Waberer L; Hinke A; Bauer M; Massa C; Seliger B; Wickenhauser C; Bokemeyer C; Hegewisch-Becker S; Binder M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34315821
[TBL] [Abstract][Full Text] [Related]
31. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
[TBL] [Abstract][Full Text] [Related]
32. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Kaufman HL; Russell J; Hamid O; Bhatia S; Terheyden P; D'Angelo SP; Shih KC; Lebbé C; Linette GP; Milella M; Brownell I; Lewis KD; Lorch JH; Chin K; Mahnke L; von Heydebreck A; Cuillerot JM; Nghiem P
Lancet Oncol; 2016 Oct; 17(10):1374-1385. PubMed ID: 27592805
[TBL] [Abstract][Full Text] [Related]
33. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
Pujade-Lauraine E; Fujiwara K; Dychter SS; Devgan G; Monk BJ
Future Oncol; 2018 Sep; 14(21):2103-2113. PubMed ID: 29584456
[TBL] [Abstract][Full Text] [Related]
34. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.
Grenga I; Donahue RN; Lepone LM; Richards J; Schlom J
Clin Transl Immunology; 2016 May; 5(5):e83. PubMed ID: 27350882
[TBL] [Abstract][Full Text] [Related]
35. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
Della Corte CM; Fasano M; Ciaramella V; Cimmino F; Cardnell R; Gay CM; Ramkumar K; Diao L; Di Liello R; Viscardi G; Famiglietti V; Ciardiello D; Martini G; Napolitano S; Tuccillo C; Troiani T; Martinelli E; Wang J; Byers L; Morgillo F; Ciardiello F
J Exp Clin Cancer Res; 2022 Mar; 41(1):109. PubMed ID: 35346313
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety profile of avelumab monotherapy.
Zhao B; Gao M; Zhao H; Zhao J; Shen X
Crit Rev Oncol Hematol; 2021 Oct; 166():103464. PubMed ID: 34461272
[TBL] [Abstract][Full Text] [Related]
38. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
39. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
[TBL] [Abstract][Full Text] [Related]
40. Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824).
Jochems C; Tritsch SR; Pellom ST; Su Z; Soon-Shiong P; Wong HC; Gulley JL; Schlom J
Oncotarget; 2017 Sep; 8(43):75217-75231. PubMed ID: 29088859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]